33620 Results

People

  1. Ladanyi
    Ladanyi
  2. Giralt
    Giralt
  3. Motzer
    Motzer
  4. Reuter
    Reuter
  5. Perales
    Perales
  6. Scher
    Scher
  7. Zelenetz
    Zelenetz
  8. Berger
    Berger
  9. Al-Ahmadie
    Al-Ahmadie
  10. O'Reilly
    O'Reilly

Groups

  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)
  7. Department of Pathology and Laboratory Medicine (5172)
  8. Surgery (4871)
  9. Sloan Kettering Institute Faculty (3826)
  10. Sloan Kettering Institute Postdocs (3612)
  1. "Meeting abstract"
Formats
  1. Meeting Abstract (33620)
Groups
  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)

More Groups

People
  1. Marc Ladanyi (641)
  2. Sergio Giralt (632)
  3. Robert Motzer (574)
  4. Victor Reuter (568)
  5. Miguel-Angel Perales (482)
  6. Howard Scher (463)

More People

Years
  1. 2025 (295)
  2. 2024 (1694)
  3. 2023 (1954)
  4. 2022 (2196)
  5. 2021 (1731)
  6. 2020 (1901)

More Years

Publications
  1. Journal of Clinical Oncology (6252)
  2. Blood (3939)
  3. Laboratory Investigation (1846)
  4. Cancer Research (1822)
  5. International Journal of Radiation Oncology, Biology, Physics (1643)
  6. Modern Pathology (1494)

More Publications

Publishers
  1. American Society of Clinical Oncology (6251)
  2. Elsevier Inc. (4694)
  3. American Society of Hematology (3939)
  4. American Association for Cancer Research (3045)
  5. Nature Publishing Group (2151)
  6. Oxford University Press (2096)

More Publishers

Results (33620)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • DASL-HiCaP: Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP1801). A randomized phase 3 double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation
    Meeting Abstract

    McBride, S. M.; Niazi, T.; Williams, S.; Davis, I. D.; Stockler, M. R.; Martin, A. J.; Bracken, K.; Roncolato, F. T.; Horvath, L.; Sengupta, S.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Association between biomarkers and clinical outcomes of lenvatinib + pembrolizumab in advanced renal cell carcinoma (RCC): Results from Study 111/KEYNOTE-146
    Meeting Abstract

    Lee, C. H.; Rasco, D. W.; Rao, A.; Taylor, M. H.; Hsieh, J. J.; Pinto, A.; Vogelzang, N. J.; Cao, Z. A.; Suttner, L.; Loboda, A.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Incidence and clinical outcomes of HER2-altered bladder cancer (BC) patients (pts)
    Meeting Abstract

    Lattanzi, M.; Niederhausern, A.; Zheng, J.; Bahadur, N.; Nichols, C.; Barton, L.; Gandhi, F.; Chan, K.; Insinga, A.; Philip, J.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • A survey study of prevention and treatment patterns by academic and community oncologists for hand-foot skin reaction associated with vascular endothelial growth factor receptor inhibitor (VEGFRi) therapy
    Meeting Abstract

    Lacouture, M. E.; Anadkat, M. J.; Patel, A. B.; Marathe, O. S.; Webb, M. L.; Tyler, R. C.; Chen, L.; Wu, C.; Li, W.; Ju, J.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • PROTEUS: A randomized, double-blind, placebo (PBO)-controlled, phase 3 trial of apalutamide (APA) plus androgen deprivation therapy (ADT) versus PBO plus ADT prior to radical prostatectomy (RP) in patients (pts) with localized or locally advanced high-risk prostate cancer (PC)
    Meeting Abstract

    Kibel, A. S.; Gleave, M.; Brookman-May, S. D.; Kim, W.; Evans, C. P.; Efstathiou, E.; Kantoff, P. W.; Ross, A.; Shore, N. D.; Briganti, A.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • A phase II study of talazoparib and avelumab in VHL deficient clear cell renal cell carcinoma
    Meeting Abstract

    Kotecha, R.; Lee, C. H.; McHugh, D. J.; Dadoun, C.; Knezevic, A.; Carlo, M. I.; Feld, E.; Shapnik, N.; Shah, N. J.; Feldman, D. R.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Clinical annotations for prostate cancer research: Defining data elements, creating a reproducible analytical pipeline, and assessing data quality
    Meeting Abstract

    Keegan, N. M.; Vasselman, S. E.; Barnett, E.; Nweji, B.; Carbone, E.; Blum, A.; Morris, M. J.; Rathkopf, D. E.; Slovin, S. F.; Danila, D. C.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Part 1 results from NOVA-II, a randomized, double-blind, vehicle-controlled phase II study evaluating the safety and efficacy of OQL011 on VEGFR inhibitor associated hand-foot skin reaction in cancer patients
    Meeting Abstract

    Lacouture, M. E.; Patel, A. B.; Le Boeuf, N. R.; Marathe, O. S.; Leventhal, J.; Choi, J. N.; Lam, E. T.; Kaffenberger, B. S.; Voss, M. H.; Webb, M. L.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • IRONMAN: The international registry for men with advanced prostate cancer
    Meeting Abstract

    George, D. J.; Mucci, L. A.; Kantoff, P. W.; Villanti, P.; Vinson, J.; Gerke, T. A.; Hyslop, T.; Rencsok, E.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Piflufolastat F 18-PET/CT in prostate cancer patients: An analysis of OSPREY (Cohorts A and B) standardized uptake value (SUV) results stratified by PSA and Gleason score
    Meeting Abstract

    Gorin, M. A.; Rowe, S. P.; Pienta, K. J.; Carroll, P. R.; Pouliot, F.; Probst, S.; Saperstein, L.; Preston, M.; Alva, A. S.; Patnaik, A.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save